静脉注射免疫球蛋白未能改善接受ECMO治疗的ARDS患者
该回顾性研究纳入ICU中接受ECMO治疗的ARDS患者,IVIG组29例在ARDS早期接受静脉IgM富集免疫球蛋白治疗3天,对照组28例未接受。两组基线特征无差异,但IVIG组氧合指数显著低于对照组。结果显示两组在ICU住院时间、通气参数、炎症程度或总体生存方面均无显著差异。作者结论为,加用IgM富集免疫球蛋白对需要ECMO支持的严重ARDS患者无有益作用。
要点
- 接受ECMO的严重ARDS患者加用静脉IgM富集免疫球蛋白3天,总体生存无显著差异。
- IVIG组与对照组在ICU住院时间和通气参数方面无差异。
- 两组炎症程度无显著差异。
- IVIG组基线氧合指数显著低于对照组。
适用人群与场景
- 入住ICU并接受ECMO治疗的ARDS患者,IVIG组29例,对照组28例。
处置流程与药物剂量
- IVIG组在ARDS初始阶段接受静脉IgM富集免疫球蛋白治疗3天;对照组未接受该治疗。
研究设计与关键结果
- 回顾性分析:IVIG组29例与对照组28例,两组基线特征无差异,但IVIG组氧合指数显著低于对照组。
- 两组ICU住院时间无差异。
- 两组通气参数无差异。
- 两组炎症程度无显著差异。
- 两组总体生存无显著差异。
证据类型、等级与局限
- 证据类型:回顾性分析;局限:原文未报告局限性。
对床旁实践的改变
- 作者结论:加用IgM富集免疫球蛋白对需要ECMO支持的严重ARDS患者无有益作用。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Acute respiratory distress syndrome (ARDS) is associated with high mortality rates. ARDS patients suffer from severe hypoxemia, and extracorporeal membrane oxygenation (ECMO) therapy may be necessary to ensure oxygenation. ARDS has various etiologies, including trauma, ischemia-reperfusion injury or infections of various origins, and the associated immunological responses may vary. To support the immunological response in this patient collective, we used intravenous IgM immunoglobulin therapy to enhance the likelihood of pulmonary recovery.
METHODS: ARDS patients admitted to the intensive care unit (ICU) who were placed on ECMO and treated with (IVIG group; n = 29) or without (control group; n = 28) intravenous IgM-enriched immunoglobulins for 3 days in the initial stages of ARDS were analyzed retrospectively.
RESULTS: The baseline characteristics did not differ between the groups, although the IVIG group showed a significantly reduced oxygenation index compared to the control group. We found no differences in the length of ICU stay or ventilation parameters. We did not find a significant difference between the groups for the extent of inflammation or for overall survival.
CONCLUSION: We conclude that administration of IgM-enriched immunoglobulins as an additional therapy did not have a beneficial effect in patients with severe ARDS requiring ECMO support.
TRIAL REGISTRATION: Clinical Trials: NCT02961166; retrospectively registered.
参考来源
- Prohaska S, Schirner A, Bashota A, et al. Intravenous immunoglobulin fails to improve ARDS in patients undergoing ECMO therapy. J Intensive Care. 2018. PMID: 29497534. doi:10.1186/s40560-018-0278-8
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。